{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:00:24Z","timestamp":1789999224071,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06201-3","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:08:24Z","timestamp":1789952904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Efficacy of Mesenchymal Stem Cells at the Level of Biomarkers in Multiple Sclerosis: A Systematic Review"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6330-4237","authenticated-orcid":false,"given":"Shahrzad","family":"Najafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-1297","authenticated-orcid":false,"given":"Parizad","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-046X","authenticated-orcid":false,"given":"Mohammad Amin Bayat","family":"Tork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8442-7439","authenticated-orcid":false,"given":"Sahar","family":"Ghorbanikalateh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3555-1496","authenticated-orcid":false,"given":"Sahel","family":"Ghorbanikalateh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4627-1071","authenticated-orcid":false,"given":"Fatemeh Ghorbani","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2242-9794","authenticated-orcid":false,"given":"Sajad","family":"Sahab-Negah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"11","key":"6201_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293908","volume":"18","author":"T Kr\u00e5kenes","year":"2023","unstructured":"Kr\u00e5kenes T, Wergeland S, Al-Sharabi N, Mohamed-Ahmed S, Fromreide S, Costea D-E et al (2023) The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination. PLoS ONE 18(11):e0293908","journal-title":"PLoS ONE"},{"issue":"1","key":"6201_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.clim.2011.03.004","volume":"142","author":"M Comabella","year":"2012","unstructured":"Comabella M, Khoury SJ (2012) Immunopathogenesis of multiple sclerosis. Clin Immunol 142(1):2\u20138","journal-title":"Clin Immunol"},{"key":"6201_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104958","volume":"79","author":"S Manche","year":"2023","unstructured":"Manche S, Probst Y (2023) Exploring the socio-ecological factors impacting lifestyle management of multiple sclerosis: a scoping review. Mult Scler Relat Disord 79:104958","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"6201_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.expneurol.2010.06.003","volume":"225","author":"JL Jones","year":"2010","unstructured":"Jones JL, Coles AJ (2010) New treatment strategies in multiple sclerosis. Exp Neurol 225(1):34\u201339","journal-title":"Exp Neurol"},{"issue":"4","key":"6201_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1517\/13543784.12.4.689","volume":"12","author":"H Wiendl","year":"2003","unstructured":"Wiendl H, Kieseier BC (2003) Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 12(4):689\u2013712","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"6201_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/WCO.0000000000000818","volume":"33","author":"M Absinta","year":"2020","unstructured":"Absinta M, Lassmann H, Trapp BD (2020) Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol 33(3):277\u2013285","journal-title":"Curr Opin Neurol"},{"key":"6201_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00967","volume":"11","author":"Z Lu","year":"2020","unstructured":"Lu Z, Zhu L, Liu Z, Wu J, Xu Y, Zhang C-J (2020) IV\/IT hUC-MSCs infusion in RRMS and NMO: a 10-year follow-up study. Front Neurol 11:967","journal-title":"Front Neurol"},{"issue":"8","key":"6201_CR8","first-page":"872","volume":"26","author":"S Najafi","year":"2023","unstructured":"Najafi S, Najafi P, Farkhad NK, Torshizi GH, Darban RA, Boroumand AR et al (2023) Mesenchymal stem cell therapy in amyotrophic lateral sclerosis (ALS) patients: a comprehensive review of disease information and future perspectives. Iran J Basic Med Sci 26(8):872","journal-title":"Iran J Basic Med Sci"},{"issue":"3","key":"6201_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031365","volume":"25","author":"S Gavasso","year":"2024","unstructured":"Gavasso S, Kr\u00e5kenes T, Olsen H, Evjenth EC, Ytterdal M, Haugs\u00f8en JB et al (2024) The therapeutic mechanisms of mesenchymal stem cells in MS\u2014a review focusing on neuroprotective properties. Int J Mol Sci 25(3):1365","journal-title":"Int J Mol Sci"},{"key":"6201_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116830","volume":"235","author":"SR Mansoor","year":"2019","unstructured":"Mansoor SR, Zabihi E, Ghasemi-Kasman M (2019) The potential use of mesenchymal stem cells for the treatment of multiple sclerosis. Life Sci 235:116830","journal-title":"Life Sci"},{"issue":"1","key":"6201_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/13524585221122156","volume":"29","author":"JA Cohen","year":"2023","unstructured":"Cohen JA, Lublin FD, Lock C, Pelletier D, Chitnis T, Mehra M et al (2023) Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis. Mult Scler J 29(1):92\u2013106","journal-title":"Mult Scler J"},{"issue":"3","key":"6201_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/WCO.0000000000000336","volume":"29","author":"M Comabella","year":"2016","unstructured":"Comabella M, Sastre-Garriga J, Montalban X (2016) Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. Curr Opin Neurol 29(3):254\u2013262","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"6201_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029058","volume":"9","author":"A Paul","year":"2019","unstructured":"Paul A, Comabella M, Gandhi R (2019) Biomarkers in multiple sclerosis. Cold Spring Harb Perspect Med 9(3):a029058","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"6201_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1515\/cclm-2017-0958","volume":"56","author":"A Kopkova","year":"2018","unstructured":"Kopkova A, Sana J, Fadrus P, Slaby O (2018) Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors. Clinical Chemistry and Laboratory Medicine (CCLM) 56(6):869\u2013879","journal-title":"Clinical Chemistry and Laboratory Medicine (CCLM)"},{"issue":"1","key":"6201_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1586\/1744666X.2015.991315","volume":"11","author":"I Raphael","year":"2015","unstructured":"Raphael I, Webb J, Stuve O, Haskins W, Forsthuber T (2015) Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol 11(1):69\u201391","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"6201_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J et al (2023) The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth 21(3):494\u2013506","journal-title":"JBI Evid Synth"},{"issue":"3","key":"6201_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.11124\/JBIES-23-00268","volume":"22","author":"TH Barker","year":"2024","unstructured":"Barker TH, Habibi N, Aromataris E, Stone JC, Leonardi-Bee J, Sears K et al (2024) The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth 22(3):378\u2013388","journal-title":"JBI Evid Synth"},{"issue":"11","key":"6201_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","volume":"20","author":"A Uccelli","year":"2021","unstructured":"Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L et al (2021) Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol 20(11):917\u2013929","journal-title":"Lancet Neurol"},{"issue":"1_suppl","key":"6201_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3727\/096368914X685005","volume":"23","author":"J-F Li","year":"2014","unstructured":"Li J-F, Zhang D-J, Geng T, Chen L, Huang H, Yin H-L et al (2014) The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant 23(1_suppl):113\u2013122","journal-title":"Cell Transplant"},{"issue":"5","key":"6201_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195891","volume":"13","author":"O Fern\u00e1ndez","year":"2018","unstructured":"Fern\u00e1ndez O, Izquierdo G, Fern\u00e1ndez V, Leyva L, Reyes V, Guerrero M et al (2018) Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I\/II safety and feasibility study. PLoS ONE 13(5):e0195891","journal-title":"PLoS ONE"},{"issue":"6","key":"6201_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.msard.2014.08.002","volume":"3","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR et al (2014) Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord 3(6):696\u2013704","journal-title":"Mult Scler Relat Disord"},{"key":"6201_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-018-1433-7","volume":"16","author":"NH Riordan","year":"2018","unstructured":"Riordan NH, Morales I, Fern\u00e1ndez G, Allen N, Fearnot NE, Leckrone ME et al (2018) Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med 16:1\u201312","journal-title":"J Transl Med"},{"key":"6201_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103779","volume":"61","author":"JA Berard","year":"2022","unstructured":"Berard JA, Freedman MS, Marrie RA, Marriott JJ, Atkins HL, Szwajcer D et al (2022) Mesenchymal stem cell therapy and cognition in MS: preliminary findings from a phase II clinical trial. Mult Scler Relat Disord 61:103779","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"6201_CR24","volume":"5","author":"LE Baldassari","year":"2019","unstructured":"Baldassari LE, Planchon SM, Bermel RA, Nakamura K, Fisher E, Feng J et al (2019) Serum neurofilament light chain concentration in a phase 1\/2 trial of autologous mesenchymal stem cell transplantation. Mult Scler J Exp Transl Clin 5(4):2055217319887198","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"4","key":"6201_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458517703802","volume":"24","author":"JA Cohen","year":"2018","unstructured":"Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ et al (2018) Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler J 24(4):501\u2013511","journal-title":"Mult Scler J"},{"issue":"2","key":"6201_CR26","first-page":"205521731985603","volume":"5","author":"J Feng","year":"2019","unstructured":"Feng J, Offerman E, Lin J, Fisher E, Planchon SM, Sakaie K et al (2019) Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler J-Exp, Transl Clin 5(2):2055217319856035","journal-title":"Mult Scler J-Exp, Transl Clin"},{"key":"6201_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-62","author":"P Connick","year":"2011","unstructured":"Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He X-L et al (2011) The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. https:\/\/doi.org\/10.1186\/1745-6215-12-62","journal-title":"Trials"},{"issue":"1-2","key":"6201_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","volume":"227","author":"B Yamout","year":"2010","unstructured":"Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A et al (2010) Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol 227(1\u20132):185\u2013189","journal-title":"J Neuroimmunol"},{"key":"6201_CR29","doi-asserted-by":"publisher","unstructured":"Mohyeddin BM, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, Ghavamzadeh A, Nikbin B (2007) Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 4(1):50\u201357. https:\/\/doi.org\/10.22034\/iji.2007.17180","DOI":"10.22034\/iji.2007.17180"},{"issue":"4","key":"6201_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.arcmed.2013.03.007","volume":"44","author":"MM Bonab","year":"2013","unstructured":"Bonab MM, Mohajeri M, Sahraian MA, Yazdanifar M, Aghsaie A, Farazmand A et al (2013) Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells. Arch Med Res 44(4):266\u2013272","journal-title":"Arch Med Res"},{"issue":"11","key":"6201_CR31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/cns.12759","volume":"23","author":"S Dahbour","year":"2017","unstructured":"Dahbour S, Jamali F, Alhattab D, Al-Radaideh A, Ababneh O, Al-Ryalat N et al (2017) Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci Ther 23(11):866\u2013874","journal-title":"CNS Neurosci Ther"},{"issue":"12","key":"6201_CR32","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1093\/brain\/awaa333","volume":"143","author":"P Petrou","year":"2020","unstructured":"Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T et al (2020) Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 143(12):3574\u20133588","journal-title":"Brain"},{"issue":"1","key":"6201_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/stcltm\/szab017","volume":"11","author":"P Petrou","year":"2022","unstructured":"Petrou P, Kassis I, Ginzberg A, Hallimi M, Karussis D (2022) Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Transl Med 11(1):55\u201358","journal-title":"Stem Cells Transl Med"},{"key":"6201_CR34","doi-asserted-by":"publisher","DOI":"10.4067\/S0717-95022022000100143","author":"T Petriv","year":"2022","unstructured":"Petriv T, Tatarchuk M, Rybachuk O, Tsymbaliuk Y, Tsymbaliyk Y, Tsymbaliuk V (2022) Efficiency and safety of umbilical cord mesenchymal stromal\/stem cells in multiple sclerosis combined treatment. Int J Morphol. https:\/\/doi.org\/10.4067\/S0717-95022022000100143","journal-title":"Int J Morphol"},{"key":"6201_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9463314","author":"L Zeng","year":"2022","unstructured":"Zeng L, Yu G, Yang K, Xiang W, Li J, Chen H (2022) Efficacy and safety of mesenchymal stem cell transplantation in the treatment of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, and ankylosing spondylitis): a systematic review and meta\u2010analysis of randomized controlled trial. Stem Cells Int. https:\/\/doi.org\/10.1155\/2022\/9463314","journal-title":"Stem Cells Int"},{"issue":"19","key":"6201_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196311","volume":"12","author":"MA Islam","year":"2023","unstructured":"Islam MA, Alam SS, Kundu S, Ahmed S, Sultana S, Patar A et al (2023) Mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis. J Clin Med 12(19):6311","journal-title":"J Clin Med"},{"issue":"1","key":"6201_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.29328\/journal.jsctt.1001034","volume":"7","author":"KA Al-Anazi","year":"2023","unstructured":"Al-Anazi KA (2023) Update on the clinical applications of mesenchymal stem cells. J Stem Cell Ther Transplant 7(1):119\u2013121","journal-title":"J Stem Cell Ther Transplant"},{"issue":"5","key":"6201_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurad.2025.101374","volume":"52","author":"M Elhaie","year":"2025","unstructured":"Elhaie M, Koozari A, Mozafari M, Abedi I (2025) The role of MRI as a key evaluator of mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis. J Neuroradiol 52(5):101374","journal-title":"J Neuroradiol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06201-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06201-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:02:15Z","timestamp":1789995735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06201-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6201"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06201-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a systematic review of previously published literature and does not involve any new studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including images, videos, or case details).","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"911"}}